use of tumor markers in testicular, prostate, colorectal, breast, and ...

References 79
biomarkers to detect breast cancer. Clin Chem 2002;48:
1296–1304.
609. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K,
McGaughey D, et al. A novel approach toward development of
a rapid blood test for breast cancer. Clin Breast Cancer
2003;4:203–209.
610. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR,
et al. Cytokeratin-positive cells in the bone marrow and survival
of patients with stage I, II, or III breast cancer. N Engl J Med
2000;342:525–533.
611. Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM,
Qvist H, et al. Detection of isolated tumor cells in bone marrow
is an independent prognostic factor in breast cancer. J Clin Oncol
2003;21:3469–3478.
612. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes
RC, et al. A pooled analysis of bone marrow micrometastasis in
breast cancer. N Engl J Med 2005;353:793–802.
613. Chen SL, Hoehne FM, Giuliano AE. The Prognostic
Significance of Micrometastases in Breast Cancer: A SEER
Population-Based Analysis. Ann Surg Oncol 2007.
614. International (Ludwig) Breast Cancer Study Group. Prognostic
importance of occult axillary lymph node micrometastases from
breast cancers. Lancet 1990;335:1565–1568.
615. Cserni G, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S,
Bussolati G, et al. European Working Group for Breast Cancer
Screening Pathology. Pathological work-up of sentinel lymph nodes
in breast cancer. Review of current data to be considered for the
formulation of guidelines. Eur J Cancer 2003;39:1654–1667.
616. Wilke LG, Giuliano A. Sentinel lymph node biopsy in patients
with early-stage breast cancer: status of the National Clinical
Trials. Surg Clin North Am 2003;83:901–910.
617. Cristofanilli M, Hayes DF, Budd GT, Ellis M, Stopeck A,
Reuben JM, et al. Circulating tumor cells: a novel prognostic
factor for newly diagnosed metastatic breast cancer. N Engl J
Med 2005;23:1420–1430.
618. Smerage JB, Hayes DF. The measurement and therapeutic implications
of circulating tumour cells in breast cancer. Br J Cancer
2006;94:8–12.
619. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-
Lehtinen P, Malmstrom P, et al. Topoisomerase IIalpha gene
amplification predicts favorable treatment response to tailored
and dose-escalated anthracycline-based adjuvant chemotherapy
in HER-2/neu-amplified breast cancer: Scandinavian Breast
Group Trial 9401. J Clin Oncol 2006;24:2428–2436.
620. Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V.
The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and
their importance to the biology of solid tumours. Cancer Treat
Rev 2007;33:64–77.
621. National Comprehensive Cancer Network (NCCN) Clinical
Practice Guidelines in Oncology, Genetic/Familial High Risk
Assessment: Breast and Ovarian Cancer. Version 1, 2007. www.
nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed
23 May 2007).
622. National Comprehensive Cancer Network (NCCN) Clinical Practice
Guidelines in Oncology, Breast Cancer. Version 2, 2008. http://
www.nccn.org/patients/patient_gls/_english/_breast/contents.asp
(Accessed 26 August 2008).
623. Fisken J, Leonard RC, Roulston JE. Immunoassay of CA125 in
ovarian cancer: a comparison of three assays for use in diagnosis
and monitoring. Dis Markers 1989;7:61–67.
624. Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire
WP, Hoskins WJ. Comparison of standard and CA-125 response
criteria in patients with epithelial ovarian cancer treated with
platinum or paclitaxel. J Clin Oncol 1999;17:501–508.
625. van der Burg ME, Lammes FB, Verweij J. The role of CA 125
in the early diagnosis of progressive disease in ovarian cancer.
Ann Oncol 1990;1:301–302.
626. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP,
Hoskins WJ, et al. Defining response of ovarian carcinoma to
initial chemotherapy according to serum CA 125. J Clin Oncol
1996;14:1545–1551.
627. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression
of ovarian carcinoma during follow-up according to CA
125: a North Thames Ovary Group Study. Ann Oncol
1996;7:361–364.
628. Camilleri-Broet S, Hardy-Bessard AC, Le TA, Paraiso D, Levrel
O, Leduc B, et al. HER-2 overexpression is an independent
marker of poor prognosis of advanced primary ovarian carcinoma:
a multicenter study of the GINECO group. Ann Oncol
2004;15:104–112.
629. Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J,
et al. HLA-G is a potential tumor marker in malignant ascites.
Clin Cancer Res 2003;9:4460–4464.
630. Sehouli J, Akdogan Z, Heinze T, Konsgen D, Stengel D, Mustea
A, Lichtenegger W. Preoperative determination of CASA
(Cancer Associated Serum Antigen) and CA-125 for the discrimination
between benign and malignant pelvic tumor mass:
a prospective study. Anticancer Res 2003;23:1115–1118.
631. Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC, Jr.,
LaPolla JP, et al. Lysophospholipids are potential biomarkers of
ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:
1185–1191.
632. Chambers SK, Gertz RE, Jr., Ivins CM, Kacinski BM. The significance
of urokinase- type plasminogen activator, its inhibitors,
and its receptor in ascites of patients with epithelial ovarian cancer.
Cancer 1995;75:1627–1633.
633. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M,
Chambers AF, Yeatman TJ. Correlation of osteopontin protein
expression and pathological stage across a wide variety of tumor
histologies. Clin Cancer Res 2004;10:184–190.
634. Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T,
Seiden MV. Utility of osteopontin as a biomarker in recurrent
epithelial ovarian cancer. Gynecol Oncol 2004;93:361–365.
635. Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll
LJ, et al. Assessment of plasma DNA levels, allelic imbalance,
and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst
2002;94:1697–1703.
636. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K,
Cheng CC, et al. Increased plasma DNA integrity in cancer
patients. Cancer Res 2003;63:3966–3968.
637. Chang HW, Ali SZ, Cho SK, Kurman RJ, Shih I. Detection of
allelic imbalance in ascitic supernatant by digital single nucleotide
polymorphism analysis. Clin Cancer Res 2002;8:2580–2585.
638. Baron-Hay S, Boyle F, Ferrier A, Scott C. Elevated serum insulinlike
growth factor binding protein-2 as a prognostic marker in
patients with ovarian cancer. Clin Cancer Res 2004;10:1796–1806.
639. National Comprehensive Cancer Network (NCCN) Clinical
Practice Guidelines in Oncology. Ovarian Cancer. Version 1, 2007.
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
(Accessed 20 June 2007.